Dergiler / Turkish Journal of Medical Sciences / 2021 / Cilt: 51 - Sayı: 4

Circulating miR-29c-3p is downregulated in patients with acromegaly

Sayfa
2081–2086
Yayın Tarihi
2022-11-03
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: Plasma miR-29c-3p expression level is downregulated in patients with acromegaly, and this is more pronounced in patients with inadequate control.Key words: Acromegaly, miR-29c-3p, miR-31-5p, miR-18a-5p

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background/aim: miRNAs control various biological functions, such as cell proliferation, differentiation, signaling pathways, apoptosis and metabolism.
📊
Temel Bulgular & Veri:The aim of the current study is to evaluate plasma miR-29c-3p, miR-31-5p and miR-18a-5p steady-state levels in acromegaly.
💡
Sonuç & Katkı:Conclusion: Plasma miR-29c-3p expression level is downregulated in patients with acromegaly, and this is more pronounced in patients with inadequate control.Key words: Acromegaly, miR-29c-3p, miR-31-5p, miR-18a-5p
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Background/aim: miRNAs control various biological functions, such as cell proliferation, differentiation, signaling pathways, apoptosis and metabolism. Recently, it has been shown that there is a relationship between changes in miRNA expression and the development of acromegaly. Studies are needed to identify new disease-specific miRNAs. The aim of the current study is to evaluate plasma miR-29c-3p, miR-31-5p and miR-18a-5p steady-state levels in acromegaly. Another aim is to investigate whether there is a difference in the levels of these miRNAs in patients with inadequate control and controlled acromegaly with somatostatin analog (SSA) therapy. These miRNAs targeting the IGF-1 gene were determined by in silico estimation. Materials and methods: The study included 30 healthy controls (HC) and 20 patients with acromegaly. Anterior pituitary functions and disease activities of patients with acromegaly were evaluated at the time of study. The miR-29c-3p, miR-31-5p and miR-18a-5p levels were measured using quantitative real-time PCR (RT-qPCR). Results: The expression level of miR-29c-3p was significantly lower in patients with acromegaly compared to the HC group (p < 0.001). This downregulation was more pronounced in patients with inadequately controlled acromegaly than in patients with acromegaly controlled with somatostatin analogues (SSA) therapy (p = 0.016). Univariate logistic regression analysis results showed that down regulation of miR-29c-3p expression increases the risk of developing acromegaly [OR (95% Cl) = 1.605 (1.142-2.257), p = 0.006]. There was no significant difference between the groups in terms of miR-31-5p and miR-18a-5p expression levels (p = 0.375 and p = 0.649, respectively). Conclusion: Plasma miR-29c-3p expression level is downregulated in patients with acromegaly, and this is more pronounced in patients with inadequate control.Key words: Acromegaly, miR-29c-3p, miR-31-5p, miR-18a-5p

🔖

Bu Makaleye Atıf Yap

ÖZTÜRK, K. H., KORKMAZ, H., TORUS, B. (2022). Circulating miR-29c-3p is downregulated in patients with acromegaly. Turkish Journal of Medical Sciences, Cilt: 51 - Sayı: 4, 2081–2086. https://ajindex.com/articles/609797

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Akirov A, Asa SL, Amer L, Shimon I, Ezzat S. The clinicopathological spectrum of acromegaly. Journal of Clinical Medicine 2019
  2. 8 (11): 1962. doi: 10.3390/jcm8111962 2. Feng Y, Mao ZG, Wang X, Du Q, Jian M et al. MicroRNAs and target genes in pituitary adenomas. Hormone and Metabolic Research 2018
  3. 50 (3): 179-192. doi: 10.1055/a-0585-7410 3. Mao ZG, He DS, Zhou J, Yao B, Xiao WW et al. Differential expression of microRNAs in GH-secreting pituitary adenomas. Diagnostic Pathology 2010
  4. doi: 10.1186/1746-1596-5-79 4. Di Ieva A, Butz H, Niamah M, Rotondo F, De Rosa S et al. MicroRNAs as biomarkers in pituitary tumors. Neurosurgery 2014
  5. 75 (2): 181-189. doi: 10.1227/NEU.0000000000000369 5. Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH et al. Acromegaly: an endocrine society clinical practice guideline.The Journal of Clinical Endocrinology & Metabolism 2014
  6. 99 (11): 3933-3951. doi: 10.1210/jc.2014-2700 6. Shi X, Tao B, He H, Sun Q, Fan C et al. MicroRNAs-based network: a novel therapeutic agent in pituitary adenoma. Medical Hypotheses 2012
  7. 78 (3): 380-384. doi: 10.1016/j. mehy.2011.12.001 7. Fang R, Huang Y, Xie J, Zhang J, Ji X. Downregulation of miR29c-3p is associated with a poor prognosis in patients with laryngeal squamous cell carcinoma. Diagnostic Pathology 2019
  8. 14 (1): 109. doi: 10.1186/s13000-019-0893-2 8. Chen G, Zhou T, Li Y, Yu Z, Sun L. p53 target miR-29c-3p suppresses colon cancer cell invasion and migration through inhibition of PHLDB2. Biochemical and Biophysical Research Communications 2017
  9. 487 (1): 90-95. doi: 10.1016/j. bbrc.2017.04.023 9. Wu H, Zhang W, Wu Z, Liu Y, Shi Y et al. miR-29c-3p regulates DNMT3B and LATS1 methylation to inhibit tumor progression in hepatocellular carcinoma. Cell Death & Disease 2019
  10. 10 (2): 48. doi: 10.1038/s41419-018-1281-7 10. Yan HJ, Ma JY, Wang L, Gu W. Expression and significance of circulating microRNA-31 in lung cancer patients. Medical Science Monitor 2015
  11. doi: 10.12659/MSM.893213 11. Shen K, Cao Z, Zhu R, You L, Zhang T. The dual functional role of MicroRNA-18a (miR-18a) in cancer development. Clinical and Translational Medicine 2019
  12. 8 (1): 32. doi: 10.1186/ s40169-019-0250-9 12. Humphreys KJ, McKinnon RA, Michael MZ. miR-18a inhibits CDC42 and plays a tumour suppressor role in colorectal cancer cells. PLoS One 2014
  13. 9 (11): e112288. doi: 10.1371/journal. pone.0112288 13. Liang C, Zhang X, Wang HM, Liu XM, Zhang XJ et al. MicroRNA-18a-5p functions as an oncogene b